Drug Testing and Employment: Cannabis Workplace Policies and Legal Rights

Executive Summary

Federal workplace drug testing for marijuana remains mandatory for safety-sensitive positions despite state legalization and potential federal rescheduling. The intersection of cannabis policy reform and employment law creates a complex landscape where workers in industries regulated by the Department of Transportation, Federal Aviation Administration, and other federal agencies face termination for off-duty marijuana use that would be legal under state law. As of June 2026, a Congressional committee explicitly directed federal regulators to maintain marijuana testing requirements for commercial truck drivers regardless of the Drug Enforcement Administration's ongoing rescheduling process, underscoring the disconnect between evolving cannabis policy and workplace safety regulations. This directive affects approximately 3.5 million commercial driver's license holders nationwide and signals that employment protections for cannabis consumers will lag behind broader legalization efforts. The issue touches every sector of the cannabis industry, from cultivation workers to dispensary employees, and affects patients using medical marijuana in 38 states who risk losing their jobs despite legal prescriptions.

Why This Matters

Employment drug testing policies determine whether millions of Americans can access both cannabis and their livelihoods simultaneously. The stakes extend far beyond individual workers. According to the Bureau of Labor Statistics, approximately 56% of American employers conduct drug testing, with pre-employment screening affecting an estimated 43 million job applicants annually. The commercial transportation sector alone employs 15.5 million workers subject to Department of Transportation drug testing mandates under 49 CFR Part 40. For the cannabis industry itself, the employment testing paradox creates operational challenges. Cultivation facilities, processing operations, and dispensaries in states like California and Colorado report difficulty hiring qualified workers who can pass drug tests, even though their work involves legal cannabis. Multi-state operators face compliance burdens navigating different state employment protections while maintaining federal contractor status or interstate commerce operations. Medical cannabis patients represent a particularly vulnerable population. The Marijuana Policy Project estimates that 5.8 million Americans hold valid medical marijuana cards, yet most lack employment protections. A patient in Ohio using cannabis to manage chronic pain under the state's medical program can be legally terminated for a positive drug test, despite Ohio Revised Code § 3796 establishing a legal medical framework. Only 19 states have enacted explicit employment protections for medical marijuana patients, and even these contain broad exceptions for safety-sensitive positions. The financial implications ripple through labor markets. Quest Diagnostics, the nation's largest drug testing laboratory, reported in its 2025 Drug Testing Index that marijuana positivity rates in the general U.S. workforce reached 4.6%, the highest level in two decades. Companies face increased recruitment costs, extended hiring timelines, and potential discrimination liability. The Society for Human Resource Management calculated that the average cost-per-hire reached $4,700 in 2025, with drug testing policies eliminating otherwise qualified candidates and extending vacancy periods by an average of 18 days.

Background and History

Federal workplace drug testing emerged from the War on Drugs era and has evolved slowly despite dramatic shifts in cannabis legalization.

The Reagan Era Foundation (1986-1988)

Modern workplace drug testing originated with Executive Order 12564, signed by President Ronald Reagan on September 15, 1986. The order declared that federal employees must refrain from using illegal drugs and mandated drug-free workplace programs across executive branch agencies. The order established that "persons who use illegal drugs are not suitable for Federal employment" and directed agency heads to establish testing programs. This executive action came amid heightened concern about cocaine and crack cocaine use, but its broad language encompassed all Schedule I controlled substances, including marijuana. Congress codified these requirements through the Drug-Free Workplace Act of 1988, enacted as part of the Anti-Drug Abuse Act. The legislation required federal contractors and grantees to maintain drug-free workplace policies as a condition of receiving federal funds. The Act did not mandate drug testing but required written policies, employee awareness programs, and disciplinary actions for drug convictions. The law's reach extended federal drug policy into private sector employment, affecting millions of workers at companies with federal contracts.

Department of Transportation Mandates (1991-1994)

The transportation sector became the first industry subject to comprehensive mandatory drug testing under the Omnibus Transportation Employee Testing Act of 1991. Congress directed the Department of Transportation to establish testing programs for safety-sensitive positions in aviation, trucking, railroads, mass transit, pipelines, and maritime operations. The DOT published final rules in 49 CFR Part 40 on December 1, 1994, creating a standardized testing protocol that remains largely intact today. These regulations established a five-panel drug test screening for marijuana, cocaine, opiates, amphetamines, and phencyclidine. The marijuana cutoff concentration was set at 50 nanograms per milliliter for initial immunoassay screening and 15 ng/mL for confirmatory gas chromatography-mass spectrometry testing. The DOT framework required pre-employment testing, random testing at minimum annual rates, post-accident testing, reasonable suspicion testing, and return-to-duty testing following policy violations. Approximately 12.5 million workers fell under DOT testing jurisdiction by 1995.

State Medical Marijuana Programs Create Conflict (1996-2010)

California voters approved Proposition 215, the Compassionate Use Act, on November 5, 1996, establishing the nation's first medical marijuana program. The initiative created a direct conflict with federal employment drug testing policies. California's law provided an affirmative defense to criminal prosecution for qualified patients but included no employment protections. Employers continued terminating workers for positive marijuana tests despite valid medical recommendations. The conflict reached federal courts in multiple cases. In Ross v. RagingWire Telecommunications, Inc., the California Supreme Court ruled on January 24, 2008, that the Compassionate Use Act did not require employers to accommodate medical marijuana use. The court held that California law did not "address the respective rights and obligations of employers and employees" and that employers could enforce drug-free workplace policies despite state medical marijuana authorization. This precedent established that state legalization alone does not create employment protections. Oregon became the first state to address employment protections explicitly. The Oregon Court of Appeals ruled in Emerald Steel Fabricators, Inc. v. Bureau of Labor and Industries on June 21, 2006, that employers could not terminate workers solely for being medical marijuana patients without positive impairment evidence. However, the Oregon Supreme Court reversed this decision on April 17, 2008, holding that federal law preempted state employment protections because employers could not be required to violate the Controlled Substances Act by permitting illegal drug use.

Adult-Use Legalization Accelerates Tensions (2012-2020)

Colorado and Washington voters approved adult-use legalization on November 6, 2012, through Amendment 64 and Initiative 502 respectively. Both measures explicitly stated they did not require employers to accommodate marijuana use. Colorado's Amendment 64 included language that nothing in the measure "is intended to require an employer to permit or accommodate the use, consumption, possession, transfer, display, transportation, sale or growing of marijuana in the workplace." The Colorado Supreme Court reinforced employer rights in Coats v. Dish Network, LLC, decided on June 15, 2015. Brandon Coats, a quadriplegic medical marijuana patient, was terminated by Dish Network after testing positive for marijuana despite never using cannabis at work or being impaired on duty. The court held that marijuana use remained "unlawful" under federal law and therefore did not qualify as "lawful activity" protected by Colorado's off-duty conduct statute. The decision established that state legalization did not protect workers from termination for off-duty use. By 2020, eleven states and the District of Columbia had legalized adult-use marijuana, but employment protections remained minimal. Most legalization statutes explicitly preserved employer drug testing rights. The disconnect between legal cannabis markets and employment policies created a two-tier system where consumers could legally purchase and possess marijuana but faced termination for use.

State Employment Protections Emerge (2020-2026)

Nevada became the first state to prohibit pre-employment marijuana testing for most positions when Assembly Bill 132 took effect on January 1, 2020. The law prohibited employers from refusing to hire applicants based on positive marijuana tests, with exceptions for safety-sensitive positions, firefighters, EMTs, and positions requiring commercial driver's licenses. Nevada Revised Statutes § 613.333 established that employers could still prohibit marijuana use and maintain drug-free workplace policies but could not use pre-employment tests as a hiring barrier. New York enacted the most comprehensive employment protections through the Marijuana Regulation and Taxation Act, signed on March 31, 2021. The law prohibited discrimination against employees for off-duty legal cannabis use and restricted employer drug testing. New York Labor Law § 201-d was amended to include legal cannabis use as protected off-duty conduct. However, the law preserved employer rights to prohibit impairment at work and maintained federal contractor exemptions. New Jersey followed with the Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act, effective February 22, 2021. The law prohibited adverse employment actions based solely on positive marijuana tests and required employers to demonstrate actual impairment through observed signs and symptoms. New Jersey's approach shifted the burden to employers to document workplace impairment rather than relying on drug test results showing past use. Montana voters approved Initiative 190 on November 3, 2020, legalizing adult-use marijuana and including employment protections. Montana Code Annotated § 16-12-111 prohibited discrimination against marijuana users but preserved employer rights for safety-sensitive positions and federal contractor compliance. The law represented a middle ground between absolute employer rights and full employee protections. By June 2026, 19 states had enacted some form of employment protection for cannabis users, though the scope and strength varied dramatically. California, despite being the first medical marijuana state, still lacked statutory employment protections, leaving workers vulnerable to termination for off-duty use.

Federal Rescheduling and Congressional Response (2025-2026)

The Drug Enforcement Administration initiated a rescheduling process in 2024 following a recommendation from the Department of Health and Human Services to move marijuana from Schedule I to Schedule III of the Controlled Substances Act. The proposed rule, published in the Federal Register on May 16, 2024, triggered a public comment period that generated over 43,000 submissions. Administrative Law Judge hearings commenced in December 2025 to evaluate the scientific and legal basis for rescheduling. The potential move to Schedule III created uncertainty about workplace drug testing requirements. Schedule III substances include anabolic steroids, ketamine, and products containing less than 90 milligrams of codeine per dosage unit. Employers generally do not test for most Schedule III substances, leading some advocates to argue that rescheduling should end marijuana testing. However, federal agencies signaled that safety-sensitive position testing would continue regardless of scheduling status. On June 4, 2026, the House Appropriations Committee included directive report language in the Transportation, Housing and Urban Development funding bill explicitly requiring the Department of Transportation to maintain marijuana testing for commercial drivers regardless of DEA rescheduling outcomes. The committee stated that marijuana impairment presents safety risks distinct from scheduling classification and that DOT testing protocols should remain unchanged. This Congressional intervention demonstrated that employment testing policy would not automatically follow rescheduling and that safety-sensitive position testing enjoyed strong legislative support.

Key Players

Department of Transportation

The DOT maintains the most comprehensive mandatory drug testing program affecting 12.8 million safety-sensitive transportation workers. The agency's Drug and Alcohol Testing Program, administered by the Office of Drug and Alcohol Policy and Compliance, enforces regulations under 49 CFR Part 40. DOT testing requirements apply to Federal Motor Carrier Safety Administration-regulated commercial drivers, Federal Aviation Administration-regulated pilots and air traffic controllers, Federal Railroad Administration-regulated train crews, Federal Transit Administration-regulated transit operators, Pipeline and Hazardous Materials Safety Administration-regulated pipeline workers, and United States Coast Guard-regulated merchant mariners. The DOT has consistently stated that marijuana testing will continue regardless of state legalization or federal rescheduling. In a 2023 guidance document, the agency emphasized that testing is based on safety concerns rather than criminal scheduling status. The DOT's position creates a permanent testing regime for transportation workers even if marijuana is fully legalized federally.

Drug Enforcement Administration

The DEA controls marijuana's federal scheduling status, which influences but does not determine employment testing policies. The agency's ongoing rescheduling process, initiated by a Health and Human Services recommendation in August 2023, represents the most significant federal cannabis policy shift in decades. However, DEA Administrator Anne Milgram testified before Congress in March 2026 that rescheduling to Schedule III would not eliminate marijuana's status as a controlled substance and would not prevent federal agencies from maintaining testing programs based on safety rationales independent of scheduling.

Substance Abuse and Mental Health Services Administration

SAMHSA establishes the scientific and technical standards for federal workplace drug testing programs. The agency's mandatory guidelines, published at 88 FR 66516, specify testing procedures, laboratory certification requirements, and cutoff concentrations. SAMHSA added oral fluid testing as an alternative specimen type in 2020, expanding testing options beyond urine. The agency's National Laboratory Certification Program certifies approximately 1,800 drug testing laboratories nationwide that process an estimated 55 million federal and federally-regulated tests annually.

Equal Employment Opportunity Commission

The EEOC determines whether workplace drug testing policies violate federal anti-discrimination laws, particularly the Americans with Disabilities Act. The commission has issued guidance stating that the ADA does not protect current illegal drug use, but the definition of "illegal" depends on federal law regardless of state legalization. In a 2020 technical assistance document, the EEOC clarified that employers may enforce drug-free workplace policies and test for marijuana even in states where cannabis is legal. However, the commission has also stated that blanket exclusions of individuals with past substance use disorders may violate the ADA if the person is no longer using drugs and is qualified for the position. The EEOC has received increasing complaints from medical marijuana patients claiming disability discrimination when terminated for positive drug tests. The commission's position remains that medical marijuana use is not protected under the ADA because marijuana remains federally illegal, but this stance may shift if rescheduling or legalization occurs.

National Organization for the Reform of Marijuana Laws

NORML has advocated for employment protections for cannabis consumers since the 1970s and tracks state-by-state workplace rights. The organization's Legal Committee has filed amicus briefs in major employment discrimination cases and drafted model legislation for state employment protections. NORML's position is that employers should be prohibited from taking adverse actions based on positive drug tests alone and should be required to demonstrate actual workplace impairment. The organization maintains that cannabis metabolite testing, which can detect use weeks after consumption, does not measure impairment and should not be used for employment decisions.

U.S. Chamber of Commerce

The Chamber represents employer interests and has consistently opposed mandatory employment protections for cannabis users. The organization argues that workplace safety, productivity, and federal compliance concerns justify employer drug testing rights. In testimony before state legislatures considering employment protection bills, Chamber representatives have emphasized that employers need flexibility to maintain drug-free workplaces, particularly in safety-sensitive industries. The Chamber supports employer discretion to test for marijuana and take adverse actions based on positive results regardless of state legalization status.

American Civil Liberties Union

The ACLU has challenged workplace drug testing as a privacy violation and has represented workers terminated for off-duty marijuana use. The organization's position is that employer surveillance of off-duty legal conduct violates privacy rights and that drug testing should be limited to situations where there is reasonable suspicion of workplace impairment. The ACLU has been particularly active in challenging random drug testing programs that lack individualized suspicion and in advocating for medical marijuana patient protections under disability discrimination laws.

Legal and Regulatory Framework

Federal law establishes marijuana as a controlled substance and permits workplace drug testing, while state laws create a patchwork of employment protections and restrictions.

Controlled Substances Act

The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., classifies marijuana as a Schedule I controlled substance under 21 U.S.C. § 812(c). Schedule I designation means the substance has high abuse potential, no currently accepted medical use in treatment in the United States, and lacks accepted safety for use under medical supervision. This classification makes marijuana possession, distribution, and use illegal under federal law regardless of state legalization. The CSA does not directly address employment, but courts have consistently held that federal illegality means marijuana use is not protected conduct under state employment laws. The CSA's supremacy over state law was established in Gonzales v. Raich, decided by the Supreme Court on June 6, 2005. The Court held that federal marijuana prohibition under the Commerce Clause applied even to intrastate medical marijuana cultivation and use authorized by state law. This precedent means federal drug testing requirements and federal contractor drug-free workplace obligations override conflicting state employment protections.

Drug-Free Workplace Act

The Drug-Free Workplace Act of 1988, codified at 41 U.S.C. § 8101 et seq., requires federal contractors and grantees to maintain drug-free workplace policies. The Act does not mandate drug testing but requires written policies prohibiting controlled substance manufacture, distribution, dispensation, possession, or use in the workplace. Contractors must establish drug-free awareness programs and notify employees that controlled substance violations will result in disciplinary action. Federal contractors with agreements exceeding $100,000 must certify compliance. Approximately 1.2 million businesses hold federal contracts subject to Drug-Free Workplace Act requirements. These employers argue that state employment protections for marijuana users conflict with federal contractor obligations, creating a compliance dilemma. Courts have generally held that federal contractor status justifies marijuana testing and termination policies even in states with employment protections.

Americans with Disabilities Act

The Americans with Disabilities Act, 42 U.S.C. § 12101 et seq., prohibits employment discrimination based on disability. However, 42 U.S.C. § 12114(a) explicitly states that the term "individual with a disability" does not include "an individual who is currently engaging in the illegal use of drugs." The ADA defines "illegal use of drugs" as "the use of drugs, the possession or distribution of which is unlawful under the Controlled Substances Act." Because marijuana remains a Schedule I controlled substance, the ADA does not protect current marijuana use even when authorized by state medical marijuana laws. The ADA does protect individuals with past substance use disorders who are not currently using drugs. In addition, 42 U.S.C. § 12114(b) states that employers may prohibit illegal drug use at the workplace, require employees not to be under the influence of illegal drugs, and hold illegal drug users to the same performance standards as other employees. These provisions give employers broad authority to enforce drug-free workplace policies. Medical marijuana patients have argued that the ADA should require reasonable accommodation of their medication, similar to accommodations for other prescription drugs. However, courts have uniformly rejected this argument based on marijuana's federal illegality. The Ninth Circuit held in James v. City of Costa Mesa on September 5, 2012, that the ADA's illegal drug use exclusion applied to medical marijuana patients. The Third Circuit reached the same conclusion in Callaghan v. Darlington Fabrics Corp. on May 7, 2004.

Department of Transportation Regulations

DOT drug testing regulations at 49 CFR Part 40 establish comprehensive testing procedures for safety-sensitive transportation employees. The regulations require testing for marijuana with a 50 ng/mL initial cutoff and 15 ng/mL confirmatory cutoff for delta-9-tetrahydrocannabinol-9-carboxylic acid, the primary marijuana metabolite. Testing is required pre-employment, randomly at a minimum 50% annual rate for controlled substances, post-accident following serious incidents, based on reasonable suspicion of use, and before return to duty following a policy violation. Part 40 specifies that medical review officers must verify positive test results and provide employees an opportunity to explain legitimate medical reasons for positive results. However, 49 CFR § 40.151(e) states that "the MRO shall not verify a test negative based on information that a physician recommended or prescribed marijuana for medical purposes." This provision explicitly rejects medical marijuana as a legitimate explanation for positive tests, even in states with medical programs. DOT regulations apply to commercial driver's license holders operating commercial motor vehicles in interstate commerce under Federal Motor Carrier Safety Administration jurisdiction, pilots and air traffic controllers under Federal Aviation Administration jurisdiction, train crews under Federal Railroad Administration jurisdiction, transit vehicle operators under Federal Transit Administration jurisdiction, pipeline workers under Pipeline and Hazardous Materials Safety Administration jurisdiction, and merchant mariners under Coast Guard jurisdiction. The regulations preempt state law under the Supremacy Clause, meaning state employment protections cannot override DOT testing requirements for covered positions.

State Employment Protection Statutes

Nineteen states have enacted employment protections for cannabis users as of June 2026, though the scope varies significantly. These statutes generally fall into three categories: states prohibiting discrimination based on off-duty marijuana use, states prohibiting adverse actions based solely on positive drug tests without impairment evidence, and states providing limited protections for medical marijuana patients only. Nevada Revised Statutes § 613.333 prohibits employers from refusing to hire applicants based on positive marijuana screening tests, with exceptions for safety-sensitive positions, firefighters, emergency medical technicians, and positions requiring commercial driver's licenses. The law applies only to pre-employment testing and does not restrict testing of current employees or prohibit termination for workplace use or impairment. New York Labor Law § 201-d protects legal off-duty cannabis use as lawful recreational activity. The statute prohibits discrimination against employees for legal cannabis use outside the workplace and outside work hours. However, employers may prohibit cannabis use or impairment during work hours and may take action when an employee's cannabis use creates a specific articulable safety risk or conflicts with federal law requirements. The New York State Department of Labor issued guidance in October 2021 stating that employers cannot test for marijuana as a condition of employment except for safety-sensitive positions or federal compliance. New Jersey Statutes Annotated § 34:6B-8 prohibits taking adverse employment action based on a positive marijuana test alone. Employers must observe specific articulable symptoms of impairment during work hours to take action. The law requires employers to document observed signs such as slurred speech, impaired coordination, or behavior changes. A positive drug test showing marijuana metabolites is insufficient grounds for termination without contemporaneous impairment observations. Montana Code Annotated § 16-12-111 prohibits refusing to hire, discharging, or penalizing a person for marijuana use, but preserves employer rights to maintain drug-free workplaces and discipline employees impaired at work. The law contains broad exceptions for safety-sensitive positions and federal compliance. Connecticut General Statutes § 21a-408p prohibits discrimination against employees for off-duty cannabis use but allows employers to prohibit cannabis use during work hours and to prohibit employees from working while impaired. The law applies to both medical and adult-use cannabis and took effect on July 1, 2021.

State-by-State Breakdown

Employment protections for cannabis users vary dramatically across states, creating a complex compliance landscape for multi-state employers.

California

California legalized medical marijuana in 1996 and adult-use marijuana in 2016, but the state lacked employment protections until Assembly Bill 2188 took effect on January 1, 2024. The law prohibits discrimination based on off-duty cannabis use detected through drug tests but applies only to tests detecting non-psychoactive cannabis metabolites. Employers may still use impairment-based testing and may prohibit cannabis use and possession at work. The law exempts building and construction trades, positions requiring federal background checks, and federal contractors. California employers may continue testing for THC, which indicates recent use, while being prohibited from taking action based on carboxy-THC metabolite tests showing past use.

New York

New York's Marijuana Regulation and Taxation Act, effective March 31, 2021, provides the strongest employment protections in the nation. Employers cannot discriminate against employees for off-duty legal cannabis use and cannot test for marijuana except in limited circumstances. Pre-employment testing is prohibited except for safety-sensitive positions defined by the Department of Labor. Random testing is prohibited except where required by federal law or where employers can demonstrate a specific articulable safety risk. The law applies to all employers regardless of size. Medical marijuana patients receive additional protections under New York's medical program, which has been operational since 2016.

New Jersey

New Jersey's Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act, effective February 22, 2021, prohibits adverse employment actions based solely on positive marijuana tests. Employers must document specific articulable symptoms of impairment observed during work hours. The law requires employers to provide written notice of workplace cannabis policies and to conduct training for supervisors on detecting impairment. New Jersey employers face potential liability for wrongful termination if they cannot demonstrate observed impairment beyond a positive drug test. The law applies to employers of all sizes and covers both medical patients and adult-use consumers.

Montana

Montana voters approved adult-use legalization through Initiative 190 on November 3, 2020, with sales beginning January 1, 2022. Montana Code Annotated § 16-12-111 prohibits discrimination against marijuana users but contains broad exceptions. Employers may prohibit marijuana use and may maintain drug-free workplace policies. Safety-sensitive positions are exempt from protections, with the definition left to employer discretion. Federal contractors and positions requiring federal licensing or security clearances are exempt. Montana's protections are weaker than New York or New Jersey but stronger than states with no statutory protections.

Nevada

Nevada Revised Statutes § 613.333, effective January 1, 2020, prohibits pre-employment marijuana testing for most positions. Employers cannot refuse to hire applicants based on positive marijuana screening tests. However, the law contains broad exceptions for safety-sensitive positions, firefighters, EMTs, and positions requiring commercial driver's licenses. The statute defines safety-sensitive positions as those where impairment could result in death or serious bodily injury. Nevada employers may still test current employees and may prohibit marijuana use during work hours. The law applies only to hiring decisions and does not restrict termination of current employees for positive tests.

Connecticut

Connecticut General Statutes § 21a-408p, effective July 1, 2021, prohibits discrimination based on off-duty cannabis use. Employers cannot refuse to hire, discharge, or penalize employees for cannabis use outside the workplace. However, employers may prohibit cannabis use during work hours, prohibit employees from working while impaired, and take action when cannabis use affects job performance. The law applies to employers with one or more employees and covers both medical patients under Connecticut's program operational since 2012 and adult-use consumers under the program that began sales on January 10, 2023.

Illinois

Illinois legalized adult-use marijuana on January 1, 2020, through the Cannabis Regulation and Tax Act. The law states that employers may adopt reasonable zero-tolerance or drug-free workplace policies and may discipline employees who violate those policies. However, 410 ILCS 705/10-50 provides that employers cannot take adverse action against employees solely for off-duty cannabis use. The law does not prohibit drug testing but restricts the use of positive test results as the sole basis for employment decisions. Illinois employers must demonstrate additional grounds for termination beyond a positive marijuana test. The law exempts safety-sensitive positions and federal contractors.

Arizona

Arizona voters approved Proposition 207 on November 3, 2020, legalizing adult-use marijuana. Arizona Revised Statutes § 36-2814 prohibits discrimination against medical marijuana cardholders unless the patient is impaired at work or possesses or uses marijuana at work. The law applies only to medical patients, not adult-use consumers. Arizona employers may test for marijuana and may prohibit use, but cannot terminate medical patients based solely on positive tests without evidence of workplace impairment. The law contains exceptions for safety-sensitive positions, federal contractors, and positions requiring commercial driver's licenses. Adult-use consumers in Arizona have no employment protections.

Ohio

Ohio legalized medical marijuana through House Bill 523, effective September 8, 2016, and adult-use marijuana through Issue 2, approved November 7, 2023. Ohio Revised Code § 3796.28 states that medical marijuana law does not require employers to accommodate employee use, and employers may discharge or take adverse action against employees who use medical marijuana. Ohio provides no employment protections for medical patients or adult-use consumers. Employers may maintain zero-tolerance drug policies and may terminate employees for positive marijuana tests regardless of off-duty use or medical authorization.

Pennsylvania

Pennsylvania's Medical Marijuana Act, 35 P.S. § 10231.2103, prohibits discrimination against medical marijuana patients unless the patient is under the influence in the workplace. Employers cannot discharge or take adverse action against employees solely because of patient status. However, the law does not require employers to commit any act that would violate federal law or cause loss of federal contracts or funding. Pennsylvania employers may prohibit marijuana use and may test for marijuana, but cannot terminate medical patients based solely on positive tests without evidence of workplace impairment. The law applies only to medical patients; Pennsylvania has not legalized adult-use marijuana.

States Without Protections

Twenty-one states with legal medical or adult-use marijuana programs provide no employment protections for cannabis users. These states include Colorado, Washington, Oregon, Michigan, Massachusetts, Maine, Vermont, Alaska, and the District of Columbia. In these jurisdictions, employers may terminate employees for off-duty marijuana use despite state legalization. Courts in these states have consistently held that state legalization does not create employment rights and that employers may enforce drug-free workplace policies. Workers in these states face termination risk for legal cannabis use.

Market and Business Implications

Drug testing policies create labor market distortions, increase hiring costs, and force cannabis industry operators to navigate contradictory compliance requirements. The Quest Diagnostics Drug Testing Index reported that marijuana positivity rates in the general U.S. workforce reached 4.6% in 2025, up from 2.8% in 2017. This increase correlates with expanded state legalization and reflects growing social acceptance of cannabis use. For employers maintaining zero-tolerance policies, the rising positivity rate means a shrinking qualified applicant pool. The American Staffing Association estimated that 45% of applicants for warehouse and logistics positions fail pre-employment drug tests, with marijuana accounting for 70% of failures. Multi-state operators in the cannabis industry face unique challenges. Cultivation facilities, processing operations, and dispensaries handle federally illegal products while attempting to maintain compliant workforces. Many MSOs hold state licenses requiring background checks and compliance with state regulations, while simultaneously operating in industries where many qualified workers consume cannabis. Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs have all reported difficulty recruiting workers who can pass drug tests in states without employment protections. The financial services sector faces particular complexity. Banks and credit unions serving cannabis businesses under FinCEN guidance must maintain Bank Secrecy Act compliance programs, which often include employee drug testing. Financial institutions argue that federal banking regulations require drug-free workplaces, creating tension with state employment protections. The American Bankers Association has lobbied against state employment protection laws, arguing they conflict with federal banking compliance requirements. Federal contractors represent a significant employment sector affected by marijuana policy. Approximately 1.2 million businesses hold federal contracts, employing an estimated 22% of the U.S. workforce. These employers argue that Drug-Free Workplace Act requirements and Federal Acquisition Regulation clauses mandate marijuana testing and zero-tolerance policies. State employment protections typically contain federal contractor exemptions, but the scope of these exemptions varies. Some states exempt only employees working directly on federal contracts, while others exempt entire companies holding any federal contract. The healthcare sector faces unique considerations. Hospitals, nursing homes, and medical practices employ approximately 18 million workers, many in safety-sensitive positions. Healthcare employers argue that patient safety requires drug testing and that marijuana use by nurses, physicians, and other clinical staff poses unacceptable risks. However, healthcare workers in states with medical marijuana programs increasingly use cannabis for chronic pain, PTSD, and other conditions. The American Nurses Association has called for research on cannabis impairment and for policies distinguishing between off-duty use and workplace impairment. Insurance costs influence employer drug testing policies. Workers' compensation insurers often provide premium discounts for employers maintaining drug-free workplace programs certified under state voluntary programs. These programs typically require pre-employment testing, post-accident testing, and random testing. Employers participating in these programs receive workers' compensation premium reductions ranging from 5% to 15%, creating financial incentives to maintain marijuana testing despite state legalization. The National Council on Compensation Insurance reported that drug-free workplace program participation remained stable at approximately 38% of employers in 2025 despite expanding legalization.

What Experts Say

Stakeholders across the employment and cannabis policy landscape hold divergent views on appropriate drug testing policies, with consensus limited to the need for reliable impairment detection methods. The National Safety Council maintains that marijuana impairs cognitive and motor functions and poses safety risks in workplace settings. According to the organization's position statement updated in March 2025, employers should maintain the right to prohibit marijuana use and to test for marijuana regardless of state legalization. The NSC argues that marijuana's impairing effects can last 24 hours or longer after use, meaning off-duty consumption can affect workplace safety. The organization supports continued testing for safety-sensitive positions and opposes employment protection laws that restrict employer testing rights. The Society for Human Resource Management surveyed 1,623 HR professionals in January 2026 regarding marijuana policies. The survey found that 57% of organizations conduct pre-employment drug testing, down from 68% in 2020. Among organizations that test, 72% include marijuana in the testing panel, down from 88% in 2020. The decline reflects both difficulty finding qualified candidates and changing attitudes toward cannabis. However, 83% of respondents in safety-sensitive industries reported they